AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Filing content is currently unavailable.

Source:

Stock IONS logo
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

#1127 Ranked by Market Cap
N/A Ranked by Dividends

IONS Latest News

Aug 21, 2025
DAWNZERA� (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Jul 30, 2025
Ionis reports second quarter 2025 financial results and highlights progress on key programs
Jul 25, 2025
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
Jul 21, 2025
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
Jul 16, 2025
Ionis to hold second quarter 2025 financial results webcast

IONS Latest SEC Filings

Aug 21, 2025
[8-K] Ionis Pharmaceuticals, Inc. Reports Material Event
Aug 20, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Aug 18, 2025
[144] Ionis Pharmaceuticals, Inc. SEC Filing
Aug 8, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Aug 6, 2025
[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity

IONS Stock Data

6.82B
155.55M
0.72%
108.62%
7.27%
Biotechnology
Pharmaceutical Preparations
United States
CARLSBAD